Article
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2017
Shenoy T R, Boysen G, Wang M Y, Xu Q Z, Guo W, Koh F M, Wang C, Zhang L Z, Wang Y, Gil V, Aziz S, Christova R, Rodrigues D N, Crespo M, Rescigno P, Tunariu N, Riisnaes R, Zafeiriou Z, Flohr P, Yuan W, Knight E, Swain A, Ramalho-Santos M, Xu D Y, de Bono J, Wu H
Abstract excerpt
BACKGROUND: Deletion of the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1) is a common genomic alteration found in human prostate cancers (PCas). CHD1 loss represents a distinct PCa subtype characterized by SPOP mutation and higher genomic instability. However, the role of CHD1 in PCa development in vivo and its clinical utility remain unclear. PATIENTS AND METHODS: To study the role of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.